Excelra offers a medical chemical intelligence database to advance the "Medical Therapy Research and Development Program"

REVIEW: The platform will help accelerate "the development of medical treatment plan" to achieve the goal faster (ATOM) alliance will significantly shorten the drug discovery cycle from one year to six yearsleading global provider of data and analysis company Excelra will be based on a three-year agreement to provide GOSTAR to Lawrence Livermore National Laboratory (LLNL)GOSTAR is a small molecule medicinal chemistry intelligence database, provides support for drug design projectsThe platform will help accelerate "the development of medical treatment plan" to achieve the goal faster (ATOM) alliance will significantly shorten the drug discovery cycle from one year to six yearsExcelra ATOM Union will grant its members full access to GOSTAR LLNL'sGOSTAR very large database, contains about 800 million small molecule compounds discovered and about 40,000 species of pre-clinical / clinical drug candidates and approved drugsIn addition to regularly updated data outside, Excelra will be needed for the artificial intelligence (AI) and Machine Learning (ML) model to provide specialized data preparation and management support servicesGOSTAR is the world's largest small molecule medicinal chemistry intelligence platform includes a comprehensive overview of the hundreds of thousands of compounds, the chemical structure associated with biology, pharmacology and treatmentIt can be a strong impetus to the early stages of drug discovery and optimization phaseLLNL Bioinformaticians and ATOM R & D team leader Jonathan Allen said: "To support the work of computational modeling, experimental data organization and integration of management is the key to the front ATOM clinical drug discovery process we look forward to the fullUsing gOSTAR and Excelra expertise to improve data-driven nature of small molecules predicted "Raveendra Dayamchemical Excelra service Director, said:" gOSTAR help drug discovery researchers to grasp small molecule drugs with the representatives of the vast space biology known interaction between a target and quantitatively very pleased with LLNL to achieve cooperation, we will strongly support their drug design platform, to shorten the drug discovery cycle "
editor: Meng Meng
Related tags:a global, database pharmaceutical0 0